Evaxion Biotech A/S, a clinical research-focused biotechnology company specializing in the development of vaccines powered by AI-Immunology™, announces the success of the initial phases of its collaboration with MSD in the field of vaccines (registered trademark of Merck & Co, Inc, Rahway, NJ, United States). The vaccine development project combines the unique capabilities and know-how of both organizations.
Christian Kanstrup, CEO of Evaxion, expresses his enthusiasm: “In September last year, we announced a collaboration with a leading pharmaceutical company, and today we are proud to announce that the collaborator in question is none other than MSD. Furthermore, we welcome the successful completion of the vaccine target discovery and design phases of this collaboration and look forward to the next phase. We firmly believe that this collaboration will further validate the performance of our AI-Immunology™ platform and contribute to bringing improvements to patients’ lives by designing unique vaccines that address serious pathologies.
Using its proprietary platform, AI-Immunology™, Evaxion has identified new vaccine targets intended to combat a bacterial pathogen causing serious health problems. The conclusion of this antigen discovery and design phases marks an important milestone for the development of the EVX-B3 vaccine candidate.
Tarit Mukhopadhyay, Vice President, Head of Infectious Diseases and Vaccine Discovery at MSD Research Laboratories, said: “At MSD, we are exploring new ways to apply AI technologies in the discovery and discovery process. development. We are excited to continue our mission with the Evaxion team.
SOURCE: GlobeNewswire
